Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...